Your shopping cart is currently empty

Cyamemazine is an antipsychotic compound with sedative and anxiolytic activity. Cyamemazine is a 5-HT3, 5-HT2A, and 5-HT2C receptor antagonist with Ki values of 12 nM, 1.5 nM, and 75 nM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 5 mg | $64 | In Stock | In Stock | |
| 10 mg | $106 | In Stock | In Stock | |
| 25 mg | $222 | - | In Stock | |
| 50 mg | $378 | - | In Stock | |
| 100 mg | $645 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $71 | - | In Stock |
| Description | Cyamemazine is an antipsychotic compound with sedative and anxiolytic activity. Cyamemazine is a 5-HT3, 5-HT2A, and 5-HT2C receptor antagonist with Ki values of 12 nM, 1.5 nM, and 75 nM, respectively. |
| Targets&IC50 | 5-HT3 Receptor:75 nM (Ki), 5-HT2C Receptor:12 nM (Ki), 5-HT2A Receptor:1.5 nM (Ki) |
| In vitro | METHODS: The antagonistic effects of Cyamemazine on various receptors, such as D2, 5-HT2A, 5-HT2C, and 5-HT3 receptors, were determined through binding experiments. RESULTS: Cyamemazine showed strong antagonistic effects on D2 and 5-HT2A receptors, and relatively weaker antagonistic effects on 5-HT2C and 5-HT3 receptors. This receptor activity is associated with its anxiolytic effects [1]. |
| In vivo | METHODS: The Elevated Plus Maze (EPM) test was conducted in mice to evaluate the anxiolytic-like behavior of Cyamemazine under acute and chronic dosing conditions. RESULTS: In the acute dosing condition, Cyamemazine exhibited anxiolytic-like activity in the light/dark exploration test. In the chronic dosing condition, it increased the time spent in the open arms of the Elevated Plus Maze, demonstrating its anxiolytic effects [1]. |
| Molecular Weight | 323.46 |
| Formula | C19H21N3S |
| Cas No. | 3546-03-0 |
| Smiles | N#CC1=CC=C2SC=3C=CC=CC3N(C2=C1)CC(C)CN(C)C |
| Relative Density. | 1.21 g/cm3 |
| Storage | store under nitrogen | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (247.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (10.2 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.